Hasil Pencarian  ::  Simpan CSV :: Kembali

"Good punctuation is more than just a matter of courtesy: in workplace writing, a sentence should yield its meaning instantly. But when punctuation is haphazard, readers need to work to understand or guess at the writer's intent. "Punctuation at Work" provides readers with 18 common sense principles to live by, helping them to avoid time-wasting confusion, questions about professionalism and sometimes even serious and costly miscommunication. From hyphens and semicolons to brackets and quotation marks...all the way to ellipses (and the eternal struggle between 'that' and 'which'), this book shows readers how to use correct punctuation to make meaning clear and emphasize their most important ideas."

"Just because you're not a born writer doesn't mean you should settle for less than perfect business documents. After all, every piece you write reflects directly on the quality of the product or service your business offers. Now, this helpful guide takes the guesswork out of more than 50 commonly used business documents, including: Reports Proposals; Business plans; Presentations; Press releases; Memos; Email Newsletters; Collection letters; and, Sales materials. Arranged alphabetically and cross-referenced for easier use, the book presents clear examples of how to (and how not to) create winning materials every time. The authors' step-by-step instructions begin with an overview of the writing process, from preparation and research right through to final review and publication. Sample documents show you how your pieces should look and read, and close to 300 individual entries cover key points of grammar, style and spelling, and present strategies for writing more clearly, avoiding bias, eliminating cliches, and much more."

"Just because you're not a born writer doesn't mean you should settle for less than perfect business documents. After all, every piece you write reflects directly on the quality of the product or service your business offers. Now, this helpful guide takes the guesswork out of more than 50 commonly used business documents, including: Reports Proposals; Business plans; Presentations; Press releases; Memos; Email Newsletters; Collection letters; and, Sales materials. Arranged alphabetically and cross-referenced for easier use, the book presents clear examples of how to (and how not to) create winning materials every time. The authors' step-by-step instructions begin with an overview of the writing process, from preparation and research right through to final review and publication. Sample documents show you how your pieces should look and read, and close to 300 individual entries cover key points of grammar, style and spelling, and present strategies for writing more clearly, avoiding bias, eliminating cliches, and much more."

"With the objective of reducing the high volume of bad practices in business research, this book offers propositions for improving theory construction and empirical testing of theory especially by business scholars. It does so by covering 24 common bad practices, explaining why they are bad and how to replace all of them with a good practice."

"ABSTRAKGlimepirid adalah suatu antihiperglikemia golongan sulfonilurea untuk terapi oral diabetes melitus tipe 2. Studi ini dilakukan untuk menilai glimepirid monoterapi dalam mengendalikan gula darah (HbA1c) pada pasien DM tipe 2, dosis yang digunakan, dan profil keamanannya. Metode: Studi observasional prospektif ini dilakukan di 4 klinik pribadi di Semarang, Jambi, Mojokerto dan Medan antara Oktober 2006 sampai September 2007 pada pasien rawat jalan, pria dan wanita, umur >20 tahun, dengan DM tipe 2, HbA1c >7%, dan tidak mendapat antidiabetik oral paling sedikit 3 bulan sebelumnya. Tablet glimepirid diberikan sekali sehari selama 3 bulan. Hasil: Dari 74 pasien yang memenuhi syarat, 18 pasien tidak kembali untuk evaluasi dan 56 pasien menyelesaikan studi 3 bulan ini, terdiri dari 26 pasien baru (belum pernah mendapat obat antidiabetes) dan 30 pasien yang sebelumnya pernah diobati (dengan obat antidiabetes). Dosis glimepirid awal dan akhir tidak berbeda untuk pasien baru maupun pasien yang sebelumnya pernah diobati (awal 2,0 mg, akhir 2,3 mg). Penurunan rata-rata kadar HbA1c 1,8% untuk semua pasien, lebih besar pada pasien baru (2,3%) dibandingkan dengan pasien yang sebelumnya pernah diobati (1,3%). Berdasarkan berat massa tubuh, penurunan rata-rata kadar HbA1c pada 20 pasien dengan BB normal 1,3%, dan lebih besar pada 20 pasien obese (2,4%). Penurunan rata-rata kadar gula darah puasa pada semua pasien 54 mg/dL, lebih besar pada pasien baru (83 mg/dL) dibandingkan pasien yang pernah diobati (30 mg/dL), tetapi tidak dipengaruhi oleh berat badan. Berat badan meningkat selama studi dengan rerata 0.9 kg. Tidak ada efek samping yang dialami oleh pasien selama 3 bulan monoterapi dengan glimepirid pada studi ini. Kesimpulan: Glimepirid monoterapi pada studi observasional dalam praktek sehari-hari selama 3 bulan ini efektif dalam menurunkan kadar HbA1c dan gula darah puasa, terutama pada pasien baru. Glimepirid pada studi ini disertai dengan peningkatkan berat badan meskipun tidak bermakna secara statistik. Tidak dilaporkan adanya efek samping dalam studi ini.

---

AbstractBackground: Glimepiride is a sulphonylurea antihyperglycemic agent for oral therapy of type-2 diabetes mellitus. This study was carried out to evaluate glimepiride monotherapy in controlling blood glucose (HbA1c) in type-2 DM patients, its dosage, and safety profile. Methods: This was a prospective observational study carried out at 4 private clinics in Semarang, Jambi, Mojokerto and Medan between October 2006 and September 2007 in outpatients of both gender, aged > 20 years, with type-2 DM, HbA1c > 7%, and received no oral antidiabetic treatment for at least 3 months. Glimepiride tablet was given once daily for 3 months. Results: From 74 eligible patients, 18 patients were lost to follow-up and 56 patients completed this 3 months study, consisting of 26 treatment-naive patients and 30 previously treated patients. The initial and final doses of glimepiride were similar in both treatment-naive patients and previously treated patients (initial 2.0 mg, final 2.3 mg). The mean reduction of HbA1c levels was 1.8% (absolute) for all patients, higher in naive patients (2.3%) compared to previously treated patients (1.3%). Based on BMI, the mean reduction of HBA1c in 20 normal weight patients was 1.3%, and more marked in 20 obese patients (2.4%). The mean reduction of FBG levels in all patients was 54 mg/dL, more pronounced in naive patients ( 83 mg/dL) compared to previously treated patients (30 mg/dL), but not affected by body weight. Bodyweight was increased during the study by a mean of 0.9 kg. No adverse event was encountered in any patient during 3 months monotherapy with glimepiride in the present study. Conclusion: Glimepiride monotherapy in the present observational study in daily practice for 3 months was shown to be effective in reducing HbA1c and FBG levels, especially in treatment naive patients. Glimepiride in the present study was associated with weight gain, although not statistically significant. No adverse event was reported in the present study."

"Summary:The book argues that clarity of responsibility increases accountability and decreases corruption levels in democracies. The authors provide a number of empirical tests of this argument using an original cross-national time-series dataset, mass survey data, and a survey experimen"